MGMT Protein-HIS Epitope

<strong>MGMT Protein-HIS Epitope</strong>_x000D_ <strong>Catalog number:</strong> B2024038_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 20 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> –70°C_x000D_ <strong>Keywords:</strong> Methylated-DNA--protein-cysteine methyltransferase, EC 2.1.1.63, 6-O-methylguanine-DNA methyltransferase, MGMT, O-6-methylguanine-DNA-alkyltransferase_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1. Hegi, M. E., Diserens, A. C., Gorlia, T., et al. (2004). "Clinical trial substantiates the predictive value of O6-methylguanine-DNA methyltransferase for temozolomide in glioblastoma." *Clinical Cancer Research*, 10(1), 187-193._x000D_ _x000D_ 2. Esteller, M., Garcia-Foncillas, J., Goodman, J. F., et al. (2000). "Inactivation of the DNA-repair gene MGMT and the clinical response of glioblastomas to alkylating agents." *New England Journal of Medicine*, 343(19), 1350-1354._x000D_ _x000D_ 3. Hegi, M. E., and Stupp, R. (2009). "MGMT gene silencing and the response of glioblastomas to alkylating agents." *Nature Reviews Clinical Oncology*, 6(1), 39-51._x000D_ _x000D_ 4. Kaina, B., and Christmann, M. (2002). "O6-methylguanine-DNA methyltransferase: a target for cancer therapy." *Current Cancer Drug Targets*, 2(1), 1-12._x000D_ _x000D_ 5. Kuo, A. H., and Kahn, S. M. (2010). "MGMT promoter methylation in glioblastoma: a review of the literature and implications for therapy." *Journal of Neuro-Oncology*, 98(3), 307-313._x000D_ _x000D_ 6. Karpel-Massler, G., and M. M. (2015). "MGMT promoter methylation status in glioblastoma: a review of the literature and its implications for treatment." *Frontiers in Oncology*, 5, 1-8._x000D_ _x000D_ 7. Kahn, S. M., and Kuo, A. H. (2011). "The role of MGMT in the treatment of glioblastoma: a review of the literature." *Neurosurgical Focus*, 30(4), E1._x000D_ _x000D_ 8. Kaina, B., and Christmann, M. (2003). "The role of O6-methylguanine-DNA methyltransferase in the resistance of glioblastoma to alkylating agents." *Cancer Letters*, 206(2), 145-152._x000D_ _x000D_ 9. Stupp, R., Hegi, M. E., and Mason, W. P. (2009). "Alkylating agents in the treatment of glioblastoma: the role of MGMT." *Journal of Clinical Oncology*, 27(8), 1275-1281._x000D_ _x000D_ 10. Weller, M., and Stupp, R. (2010). "MGMT promoter methylation in glioblastoma: a prognostic marker and a therapeutic target." *Nature Reviews Neurology*, 6(1), 1-10._x000D_ <a href="MGMT">https://pubmed.ncbi.nlm.nih.gov/?term=MGMT</a>_x000D_ _x000D_ <strong>Products Related to MGMT Protein-HIS Epitope can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>